Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Breast 3Thoracic 1Sarcoma 1Gastrointestinal 1

Conditions

Breast Neoplasms 127Neoplasm Metastasis 14Neoplasms 9Advanced Breast Cancer 6Endometrial Neoplasms 5Recurrence 4Hereditary Sensory and Autonomic Neuropathies 4Triple Negative Breast Neoplasms 3Prostatic Neoplasms 3Ovarian Neoplasms 3Neoplasms, Hormone-Dependent 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Lobular 3Carcinoma, Ductal, Breast 3Squamous Cell Carcinoma of Head and Neck 2Polycystic Ovary Syndrome 2Osteoporosis 2Neoplasms by Site 2Lymphoma, Non-Hodgkin 2Head and Neck Neoplasms 2HR+/HER2- Breast Cancer 2Breast Neoplasms, Male 2Breast Diseases 2Bone Diseases, Metabolic 2Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Small Cell Lung Carcinoma 1Osteitis Deformans 1Multiple Endocrine Neoplasia Type 1 1Mesothelioma, Malignant 1

Interventions

Prednisone 102enzalutamide 74Docetaxel 72Abiraterone Acetate 67Leuprolide 47acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 45abiraterone 37apalutamide 28Prednisolone 27bicalutamide 26Zoledronic Acid 24pembrolizumab 22Goserelin 22radium Ra 223 dichloride 21darolutamide 21Triptorelin Pamoate 17cabazitaxel 15Androgen Antagonists 15sipuleucel-T 13luprolide acetate gel depot 12Injections 12Dexamethasone 12olaparib 11gallium 68 PSMA-11 10Mitoxantrone 10Pluvicto 9Ipilimumab 9Dutasteride 9Cyclophosphamide 9relugolix 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Prostatic Neoplasms × Letrozole × Clear all
NCT07288359 2026-05-27

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Novartis

Phase 1/2 Recruiting
205 enrolled
BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT07570966 2026-05-06

Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Novartis

Phase 1/2 Not yet recruiting
217 enrolled
BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT04557449 2025-10-01

CDK4i

Pfizer

Phase 2 Active not recruiting
362 enrolled
BreastGastrointestinalGenitourinarySarcomaThoracic

Adenocarcinoma of Lung, Breast Neoplasms, Liposarcoma, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡